Analyzing How Genetics May Affect Response to High Blood Pressure Medications
CompletedNCT00563901
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
High blood pressure is one of the most common health problems in the United States. There are many medications to treat high blood pressure, but there is a large variance in how people respond to these medications. It is believed that genetic variations may contribute to the inconsistent treatment response. This study will use genetic analysis to determine whether particular genes interact with high blood pressure medications to modify the risk of certain cardiovascular diseases.
Study details
- Official title
- GenHAT - Genetics of Hypertension Associated Treatments - Ancillary to ALLHAT
- Conditions
- Hypertension
- Coronary Disease
- Cerebrovascular Accident
- Sponsor
- University of Alabama at Birmingham
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI); University of Texas; University of Minnesota
- Start date
- 2000-09
- Primary completion
- 2004-05
- Sex
- All
- Age range
- from 55 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 2
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Participant in the ALLHAT study
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00563901